US 11352631
Targeted disruption of the T cell receptor
granted A61PA61P35/00
Quick answer
US patent 11352631 (Targeted disruption of the T cell receptor) held by Sangamo Therapeutics, Inc. expires Mon Jun 02 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Sangamo Therapeutics, Inc.
- Grant date
- Tue Jun 07 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 02 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 11
- CPC classes
- A61P, A61P35/00